ONCOLYTIC POLIOVIRUS IMMUNOTHERAPY OF GLIOBLASTOMA

M. Gromeier, E. Dobrikova, M. Dobrikov, M. Brown, J. Bryant, S. Threatt, S. Boulton, K. Carter, J. Herndon, A. Desjardins, H. Friedman, J. Sampson (+2 others)
2014 Neuro-Oncology  
BACKGROUND: With the exception of Burkitt lymphoma, almost all solid cancers are susceptible to infection with poliovirus, due to widespread ectopic expression of the poliovirus receptor, the onco-fetal cell adhesion molecule Necl5/CD155. We engineered a profoundly CNS-incompetent and genetically stable variant of polio through recombination of the cognate internal ribosomal entry site (IRES) with its counterpart from human rhinovirus type 2. The resulting PVSRIPO chimera is incapable of
more » ... incapable of causing poliomyelitis or encephalitis in non-human primates or human subjects, even after high-dose intracerebral inoculation, but retains excellent cytotoxic properties in malignant cells. This is due to constitutively active signal transduction pathways via Raf-Erk MAPKs to the MAPK-interacting kinase, Mnk, and the translation apparatus. METHODS: Raf-Erk-Mnk signals favor translation of mRNAs with highly
doi:10.1093/neuonc/nou208.69 fatcat:zoo2jtr2lncbnhv3mfuqus4yye